Heidelberg Pharma AG released its earnings results on Jul 10, 2025. The company reported -€0.143 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.143.

Is Heidelberg Pharma AG overvalued?

According to Wall Street analysts Heidelberg Pharma AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Heidelberg Pharma AG pay dividends?

Heidelberg Pharma AG does not currently pay dividends.

What is Heidelberg Pharma AG’s EPS estimate?

Heidelberg Pharma AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Heidelberg Pharma AG have?

Heidelberg Pharma AG has 46,784,317 shares outstanding.

What happened to Heidelberg Pharma AG’s price movement after its last earnings report?

Heidelberg Pharma AG reported an EPS of -€0.143 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.965%.

Which hedge fund is a major shareholder of Heidelberg Pharma AG?

Currently, no hedge funds are holding shares in GB:0QW5

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Heidelberg Pharma AG Stock Smart Score

Underperform

Analyst Consensus

Hold

Average Price Target:
― (―)

Technicals

Fundamentals

Return on Equity

-112.95%

Trailing 12-Months

Asset Growth

-17.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.